Tissue Regenix Group announced the appointment of an orthopedic clinical advisory board for the US as the Group continues to gain momentum within this key orthopedic market. The clinical advisory board consists of 5 experts across varying orthopedic specialities, with special emphasis in ligament reconstruction, meniscal replacement, and cartilage restoration. Included on this Board are: Steven Arnoczky, DVM—Director, Laboratory for Comparative Orthopedic Research, at Michigan State University, East Lansing, Michigan; David Caborn, MD—Clinical Professor, Orthopedic Surgery at University of Louisville, Louisville, Kentucky; Thomas Carter, MD—Team Physician for the NBA Phoenix Suns; member of The Orthopedic Clinic Association, Phoenix, Arizona Philip Davidson, MD—founder of Davidson Orthopedics in Salt Lake City, Utah; and Jack Farr II, MD— Knee restoration and Cartilage specialist at OrthoIndy in Indianapolis, Indiana. Tissue Regenix will work closely with this Board of esteemed individuals as it looks to commercialize its orthopedic products throughout the US. With the US sports medicine market valued at $3 billion, the appointment of this Board signifies the first major step towards a commercialization pathway in the US for the Group, with an initial focus on allograft (human tissue) applications. While the initial focus will be to introduce allograft tissues treated with the proprietary dCELL® process, allowing them to be stored at room temperature, Tissue Regenix will look to address unmet clinical needs for ligament reconstruction and meniscal replacement through their portfolio of OrthoPure™ products. OrthoPure™ XM (meniscus) and XT (tendon), both porcine tissue based devices, are currently undergoing clinical trials in the EU for CE Mark approval.